mTORC2-Nav1.2 signaling drives early hyperexcitability in Alzheimer’s disease mouse model Authors: Nolan M. Dvorak, Jeffrey L. Noebels Published: 2026 ABSTRACT ABSTRACTHyperexcitability is a biomarker of early-stage Alzheimer’s Disease (AD) and hastens cognitive decline later in its course. Mechanistic target of rapamycin (mTOR) signaling contributes to the slope of this trajectory, as evidenced by early increased brain expression and the rescue of hyperexcitability by genetic deletion of mTOR complex 2 (mTORC2); however, a molecular mechanism directly linking mTOR signaling to membrane hyperexcitability in early-stage AD remains elusive. Here, we show that hyperactive mTOR signaling stimulates the voltage-gated Na+ channel 1.2 (Nav1.2), a previously identified downstream phosphorylation target of mTORC2 and a key regulator of membrane electrogenesis. Augmented Nav1.2 channel function induced by hyperactive mTOR signaling requires the action of mTORC2 and is selective among major brain Nav channel isoforms. In a murine AD model, neocortical pyramidal neurons display augmented Nav1.2 channel function and hyperexcitability through a mechanism that requires mTORC2 activity. These results highlight the mTORC2-Nav1.2 interaction as a therapeutic target for attenuating pathogenic hyperexcitability in early-stage AD. Introduction Hyperexcitability in brain circuitry is an early functional biomarker of Alzheimer’s Disease (AD) [1]. It appears during the early presymptomatic or mild cognitive impairment (MCI) stages of AD prior to the onset of severe neurodegeneration associated with the later stages of the disease [2–6]. Temporal lobe hyperexcitability is present in patients with early-stage AD [2–4] and in mouse models of early-stage AD neuropathology [7–9]. Importantly, across several transgenic mouse models of AD neuropathology that carry human Aβ precursor protein (APP) mutation(s), including J20 mice [8–11], TgCRND8 mice [12], and Tg2576 mice [13], hyperexcitability emerges prior to amyloid plaque deposition and cognitive impairment, and in 3xTg-AD mice, hyperexcitability precedes neurofibrillary pathology [14]. In the APP/PS1 mouse model of AD neuropathology, targeting drivers of membrane hyperexcitability also reduces amyloid plaques and levels of soluble Aβ [15], highlighting that hyperexcitability both precedes and exacerbates classical Aβ neuropathology. In addition to intrinsic membrane hyperexcitability in murine models of AD neuropathology [8,9,14,16], other electrophysiological perturbations are observed in early-stage AD, including synaptic dysfunction and network hypersynchrony. Multiple synaptic alterations are observed in J20 mice, including deficits in long-term potentiation [17], reductions in excitatory post-synaptic currents [18] and increases in inhibitory post-synaptic currents [7]. In studies using the Tg2576 murine model of AD neuropathology, mice show increased seizure susceptibility beginning as early as 1.5 months of age, underscoring the early emergence of network hypersynchrony in AD [13]. Studies of J20 mice also reveal an early decrease in synapse number [19], which, when combined with intrinsic membrane hyperexcitability, synaptic dysfunction, and network hypersynchrony, paint a complex picture of nascent circuit instability in early-stage AD. The early circuit instability elucidated in murine models of AD neuropathology is also observed in humans, with electroencephalographic recordings showing a consistent pattern of a shift of the power spectrum to lower frequencies, a decrease in coherence of fast rhythms, and EEG complexity changes [20,21]. Translationally, this pre-plaque, hyperexcitable window represents an important biomarker and timepoint for therapeutic intervention. For example, patients with hyperexcitability in early-stage AD display accelerated rates of cognitive decline in later stages of the disease [22], and administration of the antiseizure drug levetiracetam to AD patients with hyperexcitability has shown efficacy in terms of improving spatial memory and executive function in clinical trials [23]. This strong association between hyperexcitability and cognitive impairment in AD highlights early hyperexcitability as a compelling therapeutic target with the potential to modify disease course. However, progress is limited by a critical gap in understanding the homeostatic molecular and cellular signaling mechanisms whose disruption gives rise to AD-linked hyperexcitability. One signaling pathway that is elevated in the early-stage AD brain [24,25] and is also relevant to neuronal hyperexcitability in several neurological disorders [26,27], is mechanistic target of rapamycin (mTOR). Studies of human postmortem brain tissue from MCI cases have found increased levels of phosphorylated downstream targets of mTOR signaling [28], such as AktSer473, the major downstream target of mTOR complex 2 (mTORC2) [29]. Spurred by these findings, in tandem with pre-clinical evidence showing the efficacy of rapamycin, which inhibits mTOR complex 1 (mTORC1) and mTORC2 when administered chronically [30,31], to prevent and reverse cognitive deficits in mouse models of AD neuropathology [32,33], clinical trials are currently exploring the efficacy of mTOR suppression to improve cognitive function in patients with MCI [34]. While several hypotheses have been offered to explain how modulation of mTOR signaling can improve AD cognitive deficits [35], investigations into the downstream molecular signaling mechanism underlying mTOR’s potential role in regulating excitability in AD remain limited, despite emerging evidence that targeting hyperexcitability can improve spatial memory and executive function in patients with AD that display epileptiform activity [23]. mTOR signaling is mediated by a complex of two proteins, mTORC1, and mTORC2, each selectively bound to an auxiliary protein, namely, Raptor and Rictor, respectively [36]. In a genetically engineered mouse model of mTOR hyperactivation, mice with forebrain deletion of phosphatase and tensin homolog (PTEN), one of several upstream negative regulators of mTOR function [37], display hyperexcitability [26]. Crucially, the aberrant circuit firing behavior caused by hyperactive mTOR signaling in this model was prevented by concomitant inhibition of mTORC2, achieved either by knocking down Rictor or via an anti-Rictor antisense oligonucleotide [26]. In contrast, knockout of Raptor had no effect, highlighting a central role of mTORC2 in causing hyperexcitability when mTOR signaling is elevated [26]. More recently, a differential phospho-proteomic analysis of cortical tissue from mice with either forebrain deletion of PTEN and Raptor, which display hyperexcitability, or PTEN and Rictor, which do not display hyperexcitability, revealed that the voltage-gated Na+ (Nav) channel isoform 1.2 (Nav1.2), a key ion channel regulating membrane electrogenesis, is a downstream phosphorylation target of mTORC2 and that its phosphorylation is significantly downregulated in the non-hyperexcitable genotype (PTEN + Rictor double knockout) compared to the hyperexcitable genotype (PTEN + Raptor double knockout) [27]. Furthermore, the study found that Rictor, but not Raptor, forms a protein complex with the Nav1.2 channel [27]. Interestingly, mTORC2 has previously been shown to regulate ion transport in renal tubules through the non-voltage-gated, Na+ selective ion channel ENaC [38]; however, its functional regulation of Nav channels in the brain, such as Nav1.2, remains unresolved. To that end, in the present investigation, we employed a combination of patch-clamp recordings in heterologous cells and neurons in brain slices from a mouse model of AD neuropathology (J20 mice) in tandem with targeted pharmacological and genetic manipulations to dissect a direct signaling mechanism by which hyperactive mTOR signaling contributes to hyperexcitability in early-stage AD. Crucially, 4–5-month-old J20 mice were used for this study because this model overexpresses human amyloid-β protein precursor, and mice display hyperexcitability prior to plaque deposition at this timepoint [7–9]. Furthermore, J20 mice have been extensively studied in the context of early-stage AD hyperexcitability, including in the context of membrane hyperexcitability [8], synaptic dysfunction [7,17,18], and network hypersynchrony [39]. Collectively, the pre-plaque stage of the mice at 4–5 months of age, coupled with ample evidence of early-stage AD hyperexcitability, positions it as a model well suited to study the regulatory effects of mTORC2 signaling on Nav1.2 channel function in the context of early hyperexcitability in AD. Materials and methods Salts and drugs Unless otherwise noted, salts for electrophysiological recordings were purchased from Sigma-Aldrich (St. Louis, MO, USA). VO-OHpic and RMC-5552 were purchased from MedChemExpress (Monmouth Junction, NJ, USA). Cell culture HEK293 cells stably expressing the Nav1.1 channel, Nav1.2 channel, and the Nav1.6 channel have previously been validated [40–42] and were generous gifts from Dr. Fernanda Laezza (University of Texas Medical Branch). Cells were cultured in a 1:1 mixture of DMEM and F12 (Gibco; Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco) and penicillin–streptomycin (100 units/mL-100 µg/mL; Invitrogen, Waltham, MA, USA). G418 (500 µg/mL; Invitrogen) was used to maintain stable Nav1.2 and Nav1.6 expression, and 80 µg/mL of G418 was used to maintain stable Nav1.1 expression. For experiments utilizing transient transfection, a commercially available and previously validated [43] short hairpin that selectively and efficiently knocks down Rictor and has a GFP reporter was purchased from OriGene (Rockville, MD, USA; catalog number TG307650), as well as a control short hairpin with a GFP reporter. To knockdown PTEN, a commercially available and previously validated [44] short hairpin that selectively and efficiently knocks down PTEN and has a GFP reporter was purchased from Origene (Catalog number TL320498), as well as a control short hairpin with a GFP reporter. Cells were transfected using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s instructions. Cells were assayed 72 h post-transfection. Animals Mice from the J20 line utilized in this study were backcrossed onto a C57BL/6 background for over 10 generations, maintaining heterozygosity through breeding with wild-type C57BL/6 mice (Jackson Laboratory; Bar Harbor, ME, USA). Mice were used at 4–5 months of age and were group-housed (n ≤ 5 per cage) and provided with EnviroPak nesting material and ad libitum feed and water. A 12:12 light/dark cycle was maintained throughout the experiments. All experiments were carried out in accordance with recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, and in accordance with protocol AN-602 that was approved by the Baylor College of Medicine Institutional Animal Care and Use Committee. Patch-clamp electrophysiology – general Patch pipettes were pulled from borosilicate glass capillaries (World Precision Instruments; Sarasota, FL, USA) with a resistance of 1.5–3 MΩ for voltage-clamp recordings of neurons in the slice preparation and 3–5 MΩ for recordings of HEK293 cells and current-clamp recordings. Recordings were obtained using a Multiclamp 700B amplifier (Molecular Devices; Sunnyvale, CA, USA). Capacitive transients and series resistances were compensated for by 70–80%. Recordings in which the series resistance was > 25 MΩ or the voltage error was > 5 mV were excluded from analyses [45]. These exclusion criteria were established a priori. Data acquisition and filtering occurred at 20 kHz and 5 kHz, respectively. Clampex 10 software (Molecular Devices) was used to set experimental parameters, and electrophysiological equipment was interfaced with this software using a Digidata 1400 Series (Molecular Devices). Analysis of electrophysiological data was performed using Clampfit 11 software (Molecular Devices) and GraphPad Prism 8 software (La Jolla, CA, USA). Voltage-clamp recordings of HEK293 cells Cultured cells were dissociated and plated onto glass coverslips at low density. After plating, cells were maintained in serum-free media for at least 2 h to allow cell adhesion. 2 h prior to recording, media was replaced with media containing inhibitors. After 2 h incubation with treatment, coverslips were transferred to a recording chamber filled with the following extracellular solution: 140 mM NaCl; 3 mM KCl; 1 mM MgCl2; 1 mM CaCl2; 10 mM HEPES; and 10 mM glucose (pH = 7.3). Recording pipettes were filled with an intracellular solution comprised of the following salts: 130 mM CH3O3SCs; 1 mM EGTA; 10 mM NaCl; and 10 mM HEPES (pH = 7.3). After GΩ seal formation and entry into the whole-cell configuration, two voltage-clamp protocols were performed. The current-voltage (IV) protocol entailed voltage steps from −100 mV to +30 mV from a holding potential of −70 mV. The inactivation protocol entailed a two-pulse protocol during which, from the holding potential, cells were stepped to varying potentials between −100 mV to 0 mV prior to a test pulse at −20 mV. Acquired data was analyzed as previously described [46]. Voltage-clamp recordings of ACC pyramidal neurons Prior to preparation of acute brain slices for electrophysiological recordings, mice were deeply anesthetized with isoflurane (Baxter, Deerfield, IL, USA) and subsequently decapitated. These procedures were carried out in accordance with recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, and in accordance with protocol AN-602 that was approved by the Baylor College of Medicine Institutional Animal Care and Use Committee. Acute brain slice preparations were prepared as previously described [47]. After slicing, acute brain slice preparations were transferred from a continuously oxygenated (mixture of 95% O2 and 5% CO2) and chilled tris-based artificial cerebrospinal fluid (aCSF) containing the following salts: 72 mM Tris-HCl; 18 mM Tris-Base; 1.2 mM NaH2PO4; 2.5 mM KCl; 20 mM HEPES; 20 mM sucrose; 25 mM NaHCO3; 25 mM glucose; 10 mM MgSO4; 3 mM Na pyruvate; 5 mM Na ascorbate; and 0.5 mM CaCl2 (pH = 7.4; osmolarity = 300 – 310 mOsm/L) to a recovery chamber containing 37°C tris-based aCSF. After 15 min, slices were transferred to a recovery chamber containing continuously oxygenated (mixture of 95% O2 and 5% CO2) and 37°C standard aCSF comprised of the following salts: 123.9 mM NaCl; 3.1 mM KCl; 10 mM glucose; 1 mM MgCl2; 2 mM CaCl2; 24 mM NaHCO3; and 1.16 mM NaH2PO4 (pH = 7.4; osmolarity = 300–310 mOsm/L). After at least 30 min of incubation in standard aCSF, slices were incubated for 2 h with either inhibitors or vehicle prior to recording. After incubation with vehicle or compound, slices were transferred to a recording chamber perfused with continuously oxygenated and heated standard aCSF (with the caveat that for voltage-clamp recordings, the aCSF was supplemented with 120 µM CdCl2, 1 µM ICA 121,431 (Tocris; Bristol, UK), and 100 nM AHTTX (Cayman Chemical; Ann Arbor, MI, USA) to block voltage-gated Ca2+ channels, Nav1.1 channels, and Nav1.6 channels, respectively). Voltage-clamp recordings of ACC pyramidal neurons were performed using pipettes filled with an intracellular solution comprised of the following salts: 100 mM Cs-gluconate (Hello Bio Inc.; Princeton, NJ, USA); 10 mM tetraethylammonium chloride; 5 mM 4-aminopyridine; 10 mM EGTA; 1 mM CaCl2; 10 mM HEPES; 4 mM Mg-ATP; 0.3 mM Na3-GTP; 4 mM Na2-phosphocreatine; and 4 mM NaCl (pH = 7.4 and osmolarity = 285 ± 5 mOsm/L; CsOH used to adjust pH and osmolarity). After GΩ seal formation and entry into the whole-cell configuration, a cocktail of synaptic blockers (20 µM bicuculine, 20 µM NBQX, and 100 µM AP5; synaptic blockers purchased from Tocris) was perfused to block synaptic currents. INa was elicited and measured using previously described voltage-clamp protocols [48], and data analysis was performed as previously described [48]. Current-clamp recordings of ACC pyramidal neurons Current-clamp recordings of ACC pyramidal neurons were performed similarly to voltage-clamp recordings, with a few differences. Firstly, pipettes with resistance of 3–5 MΩ were used, and the intracellular solution was comprised of the following salts: 145 mM K-gluconate; 2 mM MgCl2; 0.1 mM EGTA; 2.5 mM Na2ATP; 0.25 mM Na2GTP; 5 mM phosphocreatine; and 10 mM HEPES (pH = 7.2 and osmolarity = 290 mOsm/L). The same aCSF was used as voltage-clamp recordings, except CdCl2, ICA 121,431, and AHTTX were not added to the solution. After GΩ seal formation and entry into the whole-cell configuration, the resting membrane potential was assessed in I = 0 for approximately 1 min prior to switching the amplifier to current-clamp mode to assess intrinsic excitability. During this 1 min interval in current-clamp, the same cocktail of synaptic blockers that was used for voltage-clamp recordings was perfused to halt changes in excitability driven by synaptic activity. The current-clamp protocol to assess intrinsic excitability entailed a range of injected current stimuli ranging from −20 pA to +220 pA (Δ 10 pA; 800 ms duration). Acquired current-clamp data was analyzed as previously described [48]. Experimental design and statistical analyses The experimental design and methods for statistical analyses adhere to ARRIVE guidelines. No protocol registration was prepared or registered prior to this study. Electrophysiological experiments used a randomized-based design and analysis was not blinded. Normality was assessed, and electrophysiological data sets displayed a normal distribution. No outliers were removed. To determine sample sizes, patch-clamp studies used sample sizes similar to previously published articles [47–49]. To minimize cofounders, cells/neurons were recorded in each experimental group during each recording session to minimize variability induced by differences in cell passage, transfection, and slice quality. For data shown in Figure 1, electrophysiological parameters were compared between four groups: Vehicle (DMSO; control), PTEN inhibition alone, PTEN + mTORC1 inhibition, and PTEN + mTORC1/2 inhibition. Comparisons related to statistical analyses utilized a one-way ANOVA with post-hoc Tukey’s multiple comparisons test. The experimental unit for these experiments was each cell, and cells were assayed from N = 4 independent passages. Sampe sizes are as follows: Vehicle, activation, n = 9, inactivation, n = 8; PTEN inhibition, activation, n = 8, inactivation, n = 8; PTEN + mTORC1 inhibition, activation, n = 10, inactivation, n = 9; PTEN + mTORC1/2 inhibition, activation, n = 9, inactivation, n = 7. Figure 1.Hyperactive mTOR signaling increases Nav1.2 channel function through a mechanism requiring mTORC2 activity (A) Representative traces of Nav1.2-mediated INa elicited by HEK-Nav1.2 cells in the indicated experimental conditions in response to the depicted voltage-clamp protocol. (B) Current-voltage relationships for HEK-Nav1.2 cells in the indicated experimental conditions. (C) comparison of the peak INa density. (D) Normalized conductance plotted as a function of voltage to characterize the effects of inhibitors on the voltage-dependence of activation of Nav1.2-mediated INa. (E) Comparison of the V1/2 of activation. (F) Normalized current plotted as a function of voltage to characterize the effects of inhibitors on the voltage-dependence of inactivation of Nav1.2-mediated INa. (G) Comparison of V1/2 of inactivation. Data are individual replicates with SEM error bars. Significance was assessed using a one-way ANOVA with post-hoc Tukey’s multiple comparisons test: ns, not significant; ***p < 0.001; ****p < 0.0001.A) Showing four sets of current traces labeled DMSO (Vehicle), VO-Ohpic (PTEN Inhibition), VO-Ohpic plus 1 nanomolar RMC-5552 (PTEN and mTORC1 Inhibition) and VO-Ohpic plus 50 nanomolar RMC-5552 (PTEN, mTORC1 and mTORC2 Inhibition). A scale bar shows 40 pA/pF vertically and 4 milliseconds horizontally. A voltage-clamp protocol schematic is shown with labeled levels at minus 70 millivolt (holding potential), minus 120 millivolt, and test pulses ranging from minus 100 millivolt to posititve 30 millivolt and a step label of 5 millivolt, 27 sweeps. B) Showing a plot of current density versus voltage for four conditions. The x-axis label is Voltage (millivolt), ranging from minus 100 to 100 with labeled ticks at minus 100, minus 50, 0, 50, 100. The y-axis label is pA per pF, ranging from 0 at the top down to minus 200 at the bottom. Four series are shown in the legend: DMSO, VO-Ohpic, VO-Ohpic plus 1 nanomolar RMC-5552 and VO-Ohpic plus 50 nanomolar RMC-5552. All series form a U-shaped inward current with the most negative values near about minus 20 to minus 30 millivolt; the VO-Ohpic and VO-Ohpic plus 1 nanomolar RMC-5552 series reach more negative minima than DMSO and VO-Ohpic plus 50 nanomolar RMC-5552. C) Showing a dot-and-bar plot comparing Peak Na current density across four groups: DMSO, VO-Ohpic, VO-Ohpic plus 1 nanomolar RMC-5552 and VO-Ohpic plus 50 nanomolar RMC-5552. The y-axis label is Peak Na Current Density (pA per pF), ranging from 0 at the top to minus 300 at the bottom with labeled ticks at 0, minus 75, minus 150, minus 225, minus 300. Individual replicate points are plotted over each bar. Multiple significance brackets are shown with labels ns, three asterisks and four asterisks. D) Showing normalized conductance activation curves. The x-axis label is Voltage (millivolt), ranging from minus 100 to 0 with labeled ticks at minus 100, minus 75, minus 50, minus 25, 0. The y-axis label is G over G max, ranging from 0 to 1.25 with labeled ticks at 0, 0.25, 0.50, 0.75, 1.00, 1.25. Four sigmoidal curves are plotted for the same four conditions; values are near 0 at voltages below about minus 50 millivolt and rise to about 1.0 by about minus 20 to minus 10 millivolt. E) showing a dot-and-bar plot of Voltage one-half activation for the four groups. The x-axis lists DMSO, VO-Ohpic, VO-Ohpic plus 1 nanomolar RMC-5552, and VO-Ohpic plus 50 nanomolar RMC-5552. The y-axis label is Voltage one-half activation (millivolt), ranging from minus 60 to 0 with labeled ticks at minus 60, minus 45, minus 30, minus 15. Replicate points overlay each bar. All displayed significance brackets are labeled ns. F) Showing normalized inactivation curves. The x-axis label is Voltage (millivolt), ranging from minus 100 to 0 with labeled ticks at minus 100, minus 75, minus 50, minus 25, 0. The y-axis label is I over I max, ranging from 0 to 1.25 with labeled ticks at 0, 0.25, 0.50, 0.75, 1.00, 1.25. Four decreasing sigmoidal curves are shown; values are near 1.0 at about minus 100 millivolt and approach 0 by about minus 25 to 0 millivolt, with the VO-Ohpic plus 1 nanomolar RMC-5552 curve shifted toward less negative voltages compared with the others. G) Showing a dot-and-bar plot of Voltage one-half inactivation for the four groups. The y-axis label is Voltage one- half inactivation (millivolt), ranging from minus 100 to 0 with labeled ticks at minus 100, minus 75, minus 50, minus 25. Replicate points overlay each bar. Several significance brackets are shown with labels ns and four asterisks.Multi-panelplots of Nav1.2 currents, including current-voltage relationships and voltage-depedences of activation and inactivation, across four inhibitor conditions. Hyperactive mTOR signaling increases Nav1.2 channel function through a mechanism requiring mTORC2 activity (A) Representative traces of Nav1.2-mediated INa elicited by HEK-Nav1.2 cells in the indicated experimental conditions in response to the depicted voltage-clamp protocol. (B) Current-voltage relationships for HEK-Nav1.2 cells in the indicated experimental conditions. (C) comparison of the peak INa density. (D) Normalized conductance plotted as a function of voltage to characterize the effects of inhibitors on the voltage-dependence of activation of Nav1.2-mediated INa. (E) Comparison of the V1/2 of activation. (F) Normalized current plotted as a function of voltage to characterize the effects of inhibitors on the voltage-dependence of inactivation of Nav1.2-mediated INa. (G) Comparison of V1/2 of inactivation. Data are individual replicates with SEM error bars. Significance was assessed using a one-way ANOVA with post-hoc Tukey’s multiple comparisons test: ns, not significant; ***p < 0.001; ****p < 0.0001. For data shown in Figure 2, electrophysiological parameters were compared between four groups: shCTRL-GFP + Vehicle (control group), shCTRL-GFP + PTEN inhibition, shRictor-GFP + PTEN inhibition, and shRictor-GFP + PTEN inhibition + mTORC1/2 inhibition. Comparisons related to statistical analyses utilized a one-way ANOVA with post-hoc Tukey’s multiple comparisons test. The experimental unit for these experiments was each cell, and the cells were assayed from N = 2–3 independent transfections. Sample sizes are as follows: shCTRL-GFP + vehicle, activation, n = 12, inactivation, n = 10; shCTRL-GFP + PTEN inhibition, activation, n = 10, inactivation, n = 10; shRictor-GFP + PTEN inhibition, activation, n = 10, inactivation, n = 10; shRictor-GFP + PTEN inhibition + mTORC1/2 inhibition, activation, n = 5, inactivation, n = 5. Figure 2.Genetic knockdown of Rictor blocks the effects of hyperactive mTOR signaling on Nav1.2 channel function. (A) Representative traces of INa elicited by HEK-Nav1.2 cells in the indicated experimental conditions in response to the voltage-clamp protocol shown in Figure 1A. (B,C) Current-voltage relationship (B) and maximal INa density (C) of HEK-Nav1.2 cells belonging to experimental grounds described in A. (D) Normalized conductance plotted as a function of voltage to determine the voltage-dependence of activation of the INa of cells belonging to the experimental groups described in A. (E) Comparison of V1/2 of activation among the indicated experimental groups. (F) Normalized current plotted as a function of voltage to determine the voltage-dependence of inactivation of the INa of cells belonging to the experimental groups described in A. (G) Comparison of the V1/2 of inactivation among the indicated experimental groups. Data are individual replicates with SEM error bars. Significance was assessed using a one-way ANOVA with post hoc Tukey’s multiple comparisons test: ns, not significant; ***p < 0.001; ****p < 0.0001.A) Four sets of current traces under headings shCtrl-GFP or shRictor-GFP. Each trace set is labeled DMSO (Vehicle), VO-Ohpic (PTEN inhibition), VO-Ohpic (PTEN inhibition), and VO-Ohpic plus 50 nanomolar RMC-5552 (PTEN plus mTORC1/2 inhibition). A scale bar shows 20 pA/pF and 4 millisecond. B) Graph of current-voltage relationships. The x-axis label is Voltage (millivolt), ranging from minus 100 to 50 with labeled ticks at minus 100, minus 50, 0 and 50. The y-axis label is picoampere over picoFarad, ranging from 0 at the top down to minus 150 at the bottom. Four series of open-circle points with error bars follow a U-shape: near 0 at minus 100, decreasing to a minimum around minus 20 to minus 10, then returning toward 0 by 50. C) Individual repliates of Peak Nav1.2 Sodium Current Density across the four conditions. The y-axis label is picoampere over picoFarad, ranging from 0 at the top down to minus 300 at the bottom, with labeled ticks at minus 75, minus 150, minus 225 and minus 300. The x-axis categories are shCTRL plus DMSO, shCTRL plus VO-Ohpic, shRictor plus VO-Ohpic and shRictor plus VO-Ohpic plus 50 nanomolar RMC-5552. Individual points overlay each bar; multiple brackets show ns, three asterisks and four asterisks. D) Normalized conductance activation curves. The x-axis label is Voltage (millivolt), ranging from minus 100 to 0 with labeled ticks at minus 100, minus 75, minus 50, minus 25 and 0. The y-axis label is G over G max, ranging from 0.00 to 1.25 with labeled ticks at 0.00, 0.25, 0.50, 0.75, 1.00 and 1.25. Four sigmoidal series rise from near 0 at minus 100 to near 1.00 by about minus 10 to 0. E) Bar plus scatter plot of Voltage one-half activation (millivolt). The y-axis ranges from minus 80 to 0. The same four x-axis categories appear as in C. Brackets above comparisons are labeled ns. F) Inactivation curves. The x-axis label is Voltage (millivolt), ranging from minus 100 to 0 with labeled ticks at minus 100, minus 75, minus 50, minus 25 and 0. The y-axis label is I over I max, ranging from 0.00 to 1.25 with labeled ticks at 0.00, 0.25, 0.50, 0.75, 1.00 and 1.25. Four sigmoidal series decrease from near 1.00 at minus 100 toward near 0 by about minus 40 to minus 25. G) Bar plus scatter plot of Voltage one-half inactivation (millivolt). The y-axis ranges from minus 140 to 0 with labeled ticks at minus 35, minus 70, minus 105 and minus 140. The same four x-axis categories appear as in image C. Multiple brackets show ns, three asterisks and four asterisks.Plots of Na1.2 channel currents, including current-voltage relationships and voltage dependences of activation and inactivation, across conditions. Genetic knockdown of Rictor blocks the effects of hyperactive mTOR signaling on Nav1.2 channel function. (A) Representative traces of INa elicited by HEK-Nav1.2 cells in the indicated experimental conditions in response to the voltage-clamp protocol shown in Figure 1A. (B,C) Current-voltage relationship (B) and maximal INa density (C) of HEK-Nav1.2 cells belonging to experimental grounds described in A. (D) Normalized conductance plotted as a function of voltage to determine the voltage-dependence of activation of the INa of cells belonging to the experimental groups described in A. (E) Comparison of V1/2 of activation among the indicated experimental groups. (F) Normalized current plotted as a function of voltage to determine the voltage-dependence of inactivation of the INa of cells belonging to the experimental groups described in A. (G) Comparison of the V1/2 of inactivation among the indicated experimental groups. Data are individual replicates with SEM error bars. Significance was assessed using a one-way ANOVA with post hoc Tukey’s multiple comparisons test: ns, not significant; ***p < 0.001; ****p < 0.0001. For data shown in Figure 3, electrophysiological parameters were compared between four groups: shCTRL-GFP + Vehicle (control group), shPTEN-GFP + Vehicle, shPTEN-GFP + PTEN inhibition, and shPTEN-GFP + mTORC1/2 inhibition. Comparisons related to statistical analyses utilized a one-way ANOVA with post-hoc Tukey’s multiple comparisons test. The experimental unit for these experiments was each cell, and cells were assayed from N = 3 independent transfections. Sample sizes are as follows: shCTRL + Vehicle, activation, n = 8, inactivation, n = 8; shPTEN-GFP + Vehicle, activation, n = 6, inactivation, n = 6; shPTEN-GFP + PTEN inhibition, activation, n = 6, inactivation, n = 6; shPTEN-GFP + mTORC1/2 inhibition, activation, n = 6, inactivation, n = 6. Figure 3.Genetic knockdown of PTEN hyperactivates Nav1.2 channel function through an mTORC2-depedent mechanism. (A) Traces of INa elicited in HEK-Nav1.2 cells belonging to the indicated experimental condition. (B,C) I-V curves (B) and peak current densities (C) of cells belonging to the conditions described in (A). (D,E) Plots of the voltage-dependence of activation (D) and V1/2 of activation values (E) for cells in the conditions described in (A). (F,G) Plots of the voltage-dependence of inactivation (F) and V1/2 of inactivation values (G) for cells described in (A). Data are individual replicates with SEM error bars. Significance was assessed using a one-way ANOVA with post hoc Tukey’s multiple comparisons test: ns, not significant; **p < 0.01; ***p < 0.001.A) Four current trace groups: shCTRL-GFP with DMSO, shPTEN-GFP with DMSO, shPTEN-GFP with VO-Ohpic, and shPTEN-GFP with 50 nM RMC-5552, with a scale of 50 pA/pF and 6 ms. B) Current-voltage relationships, with minima between -20 mV and -10 mV. C) Dot and bar chart with categories matching A, showing Peak Sodium Current Density (pA/pF) ranging from 0 to -320, with significance labels ns, ** and ***. D) Sigmoidal activation curves rising from 0 to 1 between -40 mV and -10 mV. E) Dot and bar chart shows V1/2 activation (mV) values with ns labels. F) Inactivation curves decreasing from 1 to 0 between -80 mV and -30 mV. G) Dot and bar chart, shows V_1/2 inactivation values with significance labels ns, ** and ***.Plots of Nav1.2 channel traces, including plots of current-voltage relationships and the voltage depedences of activation and inactivation, across four conditions. Genetic knockdown of PTEN hyperactivates Nav1.2 channel function through an mTORC2-depedent mechanism. (A) Traces of INa elicited in HEK-Nav1.2 cells belonging to the indicated experimental condition. (B,C) I-V curves (B) and peak current densities (C) of cells belonging to the conditions described in (A). (D,E) Plots of the voltage-dependence of activation (D) and V1/2 of activation values (E) for cells in the conditions described in (A). (F,G) Plots of the voltage-dependence of inactivation (F) and V1/2 of inactivation values (G) for cells described in (A). Data are individual replicates with SEM error bars. Significance was assessed using a one-way ANOVA with post hoc Tukey’s multiple comparisons test: ns, not significant; **p < 0.01; ***p < 0.001. For data shown in Figure 4, electrophysiological parameters were compared between four groups: Vehicle (DMSO; control), PTEN inhibition alone, PTEN + mTORC1 inhibition, and PTEN + mTORC1/2 inhibition. Comparisons related to statistical analyses utilized a one-way ANOVA with post-hoc Tukey’s multiple comparisons test. The experimental unit for these experiments was each cell, and cells were assayed from N = 4 independent passages. For HEK-Nav1.1 cells, sample sizes are as follows: Vehicle, activation, n = 10, inactivation, n = 10; PTEN inhibition, activation, n = 10, inactivation, n = 10; PTEN + mTORC1 inhibition, activation, n = 10, inactivation, n = 10; PTEN + mTORC1/2 inhibition, activation, n = 10, inactivation, n = 10. For HEK-Nav1.6 cells, sample sizes are as follows: Vehicle, activation, n = 8, inactivation, n = 8; PTEN inhibition, activation, n = 8, inactivation, n = 8; PTEN + mTORC1 inhibition, activation, n = 8, inactivation, n = 8; PTEN + mTORC1/2 inhibition, activation, n = 8, inactivation, n = 8. Figure 4.mTORC2’s regulatory effects are selective for the Nav1.2 channel among major brain Nav channel isoforms. (A,H) Representative traces of INa elicited in either HEK-Nav1.1 cells (A) or HEK-Nav1.6 cells (H) treated with the indicated inhibitors in response to the same voltage-clamp protocol shown in Figure 1a. (B,I) Current-voltage relationships for either HEK-Nav1.1 cells (B) or HEK-Nav1.6 cells (I) treated with the inhibitors listed in A,H. (C,J) Comparison of the peak INa density for HEK-Nav1.1 cells (C) or HEK-Nav1.6 cells (J). (D,K) Normalized conductance plotted as a function of voltage to determine effects of inhibitors on the voltage-dependence of activation of Nav1.1-mediated INa (D) or Nav1.6-mediated INa (K). (E,L) Comparison of V1/2 of activation of Nav1.1-mediated INa (E) or Nav1.6-mediated INa (L). (F,M) Normalized current plotted as a function of voltage to determine the effects of inhibitors on the voltage-dependence of inactivation of Nav1.1-mediated INa (F) or Nav1.6-mediated INa (M). (G,N) Comparison of V1/2 of inactivation of Nav1.1-mediated INa (G) or Nav1.6-mediated INa (N). Data are individual replicates with SEM error bars. Significance was assessed using a one-way ANOVA with post-hoc Tukey’s multiple comparisons test: ns, not significant.A) Four sets of current traces for HEK-Nav1.1: DMSO (Vehicle), VO-Ohpic (PTEN inhibition), VO-Ohpic plus 1 nanomolar RMC-5552 (PTEN plus mTORC1 inhibition), and VO-Ohpic plus 50 nanomolar RMC-5552 (PTEN plus mTORC1/2 inhibition). Scale bars: 50 picoampere per picofarad and 5 millisecond. B) Current-voltage relationships. X-axis label: Voltage (millivolt), from minus 100 to 100. Y-axis label: picoampere per picofarad, from 0 to minus 120. Curves overlap, with minimum near minus 20 millivolt at about minus 110 to minus 120 pA/pF. C) Bar plus dot plot of Peak Sodium Current Density (picoampere per picofarad) from 0 to 280. Groups: DMSO, VO-Ohpic, VO-Ohpic plus 1 nanomolar RMC-5552, VO-Ohpic plus 50 nanomolar RMC-5552; all pairwise brackets labeled ns. D) Normalized conductance as a function of voltage to determine the voltage-dependence of activation. X-axis: Voltage (millivolt) minus 100 to 0. Y-axis: G over G subscript max, 0 to 1.25. Sigmoid rises from near 0 at about minus 50 mV to near 1 at about minus 20 mV. E) Voltage one-half activation (millivolt) for the four groups; brackets labeled ns. F) Inactivation curves. X-axis: Voltage (millivolt) minus 100 to 0. Y-axis: I over I subscript max, 0 to 1.25. Sigmoid falls from near 1 at about minus 90 mV to near 0 at about minus 40 mV. G) Voltage one-half inactivation (millivolt) for the four groups; brackets labeled ns. H) Four sets of current trances for HEK-Nav1.6 under the same four conditions. Scale bars: 30 picoampere per picofarad and 5 millisecond. I) Current-voltage relationships. X-axis: Voltage (millivolt) minus 100 to 100. Y-axis: picoampere per picofarad, 0 to minus 80. Curves overlap, minimum near minus 20 millivolt at about minus -70 to minus -80 pA/pF. J) Peak Sodium Current Density (picoampere per picofarad), from 0 to 160, for the four groups; brackets labeled ns. K) Normalized conductance plotted as a function of voltage to determine the voltage-dependence of activation. L) Voltage one-half activation (millivolt) for the four groups; brackets labeled ns. M) Normalized current plotted as a function of voltage to determine the voltage-dependence of inactvation. N) Voltage one-half inactivation (millivolt) for the four groups; brackets labeled ns.- Electrophysiological analyses comparing HEK-Nav1.1 and HEK-Nav1.6 responses across inhibitor conditions. mTORC2’s regulatory effects are selective for the Nav1.2 channel among major brain Nav channel isoforms. (A,H) Representative traces of INa elicited in either HEK-Nav1.1 cells (A) or HEK-Nav1.6 cells (H) treated with the indicated inhibitors in response to the same voltage-clamp protocol shown in Figure 1a. (B,I) Current-voltage relationships for either HEK-Nav1.1 cells (B) or HEK-Nav1.6 cells (I) treated with the inhibitors listed in A,H. (C,J) Comparison of the peak INa density for HEK-Nav1.1 cells (C) or HEK-Nav1.6 cells (J). (D,K) Normalized conductance plotted as a function of voltage to determine effects of inhibitors on the voltage-dependence of activation of Nav1.1-mediated INa (D) or Nav1.6-mediated INa (K). (E,L) Comparison of V1/2 of activation of Nav1.1-mediated INa (E) or Nav1.6-mediated INa (L). (F,M) Normalized current plotted as a function of voltage to determine the effects of inhibitors on the voltage-dependence of inactivation of Nav1.1-mediated INa (F) or Nav1.6-mediated INa (M). (G,N) Comparison of V1/2 of inactivation of Nav1.1-mediated INa (G) or Nav1.6-mediated INa (N). Data are individual replicates with SEM error bars. Significance was assessed using a one-way ANOVA with post-hoc Tukey’s multiple comparisons test: ns, not significant. For data shown in Figure 5, electrophysiological parameters were compared between four groups: WT + Vehicle (control group), J20 + vehicle, J20 + mTORC1 inhibition, and J20 + mTORC1/2 inhibition. Comparisons related to statistical analyses utilized a one-way ANOVA with post-hoc Tukey’s multiple comparisons test. The experimental unit for these experiments was each neuron, and slices were obtained for N = 4 mice/genotype. Sample sizes are as follows: WT + Vehicle, activation, n = 7, inactivation, n = 6; J20 + Vehicle, activation, n = 7, inactivation, n = 6; J20 + mTORC1 inhibition, activation, n = 7, inactivation, n = 7; J20 + mTORC1/2 inhibition, activation, n = 7, inactivation, n = 7. Figure 5.Neocortical pyramidal neurons in slices from 4–5 month-old J20 mice display augmented Nav1.2 channel function through a mechanism requiring mTORC2 activity. (A) Representative traces of Nav1.2-mediated INa in ACC pyramidal neurons in each indicated condition in response to the depicted voltage-clamp protocol. (B,C) Comparisons across conditions of current-voltage relationships (B) and peak Nav1.2-mediated INa density (C). (D) Normalized conductance plotted as a function of voltage to determine the voltage-dependence of activation of the Nav1.2-mediated INa. (E) Comparison of the V1/2 of activation. (F) normalized current plotted as a function of voltage to determine the voltage-dependence of inactivation of Nav1.2-mediated INa. (G) Comparison of V1/2 of inactivation. Data are individual replicates with SEM error bars. Statistical significance was assessed using a one-way ANOVA with post hoc Tukey’s multiple comparison’s test: ns, not significant; ****p < 0.0001.A) Pharmacologically isolated Nav1.2 current traces from ACC pyrmaidal neurons under four conditions: WT DMSO, J20 DMSO, J20 with 1 nM RMC-5552 (mTORC1 inhibition) and J20 with 50 nM RMC-5552 (mTORC1/2 inhibition). Scale: 15 pA/pF, 10 ms. B) Current-voltage graph, with U-shaped curves peaking negatively around -30 mV to -20 mV for the conditions described in A. C) d Peak sodium current density, with categories: WT DMSO, J20 DMSO, J20 with 1 nM RMC-5552, J20 with 50 nM RMC-5552. Y-axis: 0 to -120 pA/pF. D) Activation curves. E) V1/2 activation values for the groups described in A. F) Inactivation curves. G) V1/2 inactivation values for the groups described in A.Figure comparing the Nav1.2 sodium current of WT and J20 pyramidal neurons treated with vehicle (DMSO) and different concentrations of RMC-5552. Neocortical pyramidal neurons in slices from 4–5 month-old J20 mice display augmented Nav1.2 channel function through a mechanism requiring mTORC2 activity. (A) Representative traces of Nav1.2-mediated INa in ACC pyramidal neurons in each indicated condition in response to the depicted voltage-clamp protocol. (B,C) Comparisons across conditions of current-voltage relationships (B) and peak Nav1.2-mediated INa density (C). (D) Normalized conductance plotted as a function of voltage to determine the voltage-dependence of activation of the Nav1.2-mediated INa. (E) Comparison of the V1/2 of activation. (F) normalized current plotted as a function of voltage to determine the voltage-dependence of inactivation of Nav1.2-mediated INa. (G) Comparison of V1/2 of inactivation. Data are individual replicates with SEM error bars. Statistical significance was assessed using a one-way ANOVA with post hoc Tukey’s multiple comparison’s test: ns, not significant; ****p < 0.0001. For data shown in Figure 6, electrophysiological parameters were compared between four groups: WT + Vehicle (control group), J20 + vehicle, J20 + mTORC1 inhibition, and J20 + mTORC1/2 inhibition. Comparisons related to statistical analyses utilized a one-way ANOVA with post-hoc Tukey’s multiple comparisons test. The experimental unit for these experiments was each neuron, and slices were obtained for N = 4 mice/genotype. Sample sizes are as follows: WT + DMSO, n = 10; J20 + DMSO, n = 11; J20 + mTORC1 inhibition, n = 8; J20 + mTORC1/2 inhibition, n = 10. In total, 16 mice were used for electrophysiological studies. Figure 6.mTORC2 signaling contributes to hyperexcitability of ACC pyramidal neurons in slices from 4–5 month-old J20 mice. (A) Representative traces of APs evoked by the 200-pA injected current step in ACC pyramidal neurons belonging to the indicated experimental group. (B) Input/output plot showing the number of evoked APs as a function of injected current for ACC pyramidal neurons belonging to the experimental groups described in A. (C-E) Comparison of the maximal firing (C), membrane time constant (D), and input resistance (E) among the indicated experimental groups. Data are individual replicates with SEM error bars. Statistical significance was assessed using a one-way ANOVA with post-hoc Tukey’s multiple comparisons test: ns, not significant; ***p < 0.001; ****p < 0.0001. In (B), * denotes current steps at which the number of APs is significantly larger (p is at least < 0.05) in the J20 + DMSO and J20 + 1 nM RMC-5552 groups compared to the WT + DMSO and J20 + 50 nM RMC-5552 groups.A) Trace of evoked action potentials from ACC pyramidal neurons in the following four conditions: WT with DMSO, J20 with DMSO, J20 with 1 nM RMC-5552, and J20 with 50 nM RMC-5552. Scale: 20 mV, 150 ms; stimulus: 200 pA, 800 ms. B) Graph of evoked APs as a function of injected current. C) Plot of indvidual replicates showing max APs for WT+DMSO, J20+DMSO, J20+1 nM RMC-5552, J20+50 nM RMC-5552. D) Dot/bar chart for Tau (ms) with groups WT+DMSO, J20+DMSO, J20+1 nM RMC-5552, J20+50 nM RMC-5552. E) Dot/bar chart for input resistance (Megaohm) with groups WT+DMSO, J20+DMSO, J20+1 nM RMC-5552, J20+50 nM RMC-5552.Comparison of the intrinsic firing properties of WT versus J20 neocortical pyramidal neurons treated with vehicle (DMSO) or two different concentrations of RMC-5552. mTORC2 signaling contributes to hyperexcitability of ACC pyramidal neurons in slices from 4–5 month-old J20 mice. (A) Representative traces of APs evoked by the 200-pA injected current step in ACC pyramidal neurons belonging to the indicated experimental group. (B) Input/output plot showing the number of evoked APs as a function of injected current for ACC pyramidal neurons belonging to the experimental groups described in A. (C-E) Comparison of the maximal firing (C), membrane time constant (D), and input resistance (E) among the indicated experimental groups. Data are individual replicates with SEM error bars. Statistical significance was assessed using a one-way ANOVA with post-hoc Tukey’s multiple comparisons test: ns, not significant; ***p < 0.001; ****p < 0.0001. In (B), * denotes current steps at which the number of APs is significantly larger (p is at least < 0.05) in the J20 + DMSO and J20 + 1 nM RMC-5552 groups compared to the WT + DMSO and J20 + 50 nM RMC-5552 groups. Results Hyperactive mTOR signaling increases Nav1.2 channel function through a mechanism requiring mTORC2 activity To determine the functional regulation of the Nav1.2 channel conferred by mTORC2 signaling, we performed patch-clamp recordings in a previously validated HEK293 cell line that stably expresses the Nav1.2 channel (HEK-Nav1.2) [40] in combination with targeted pharmacological and genetic manipulations of mTOR signaling. Crucially, HEK293 cells endogenously express PTEN [50], as well as Raptor and Rictor [27]. We first investigated the effects of hyperactive mTOR signaling on Nav1.2 channel function by treating HEK-Nav1.2 cells with a previously validated potent and selective inhibitor of PTEN (VO-Ohpic; concentration: 500 nM) [51], a negative regulator of mTOR signaling, for 2 h. We found that hyperactivating mTOR signaling via pharmacological inhibition of PTEN markedly increased Nav1.2-mediated Na+ current (INa; Figure 1A–C). While hyperactivating mTOR signaling did not affect the voltage-dependence of activation of Nav1.2-mediated INa (Figure 1D,E), it did induce a significant depolarizing shift in the voltage-dependence of inactivation of Nav1.2-mediated INa (Figure 1F,G). We next dissected the role of mTORC1 versus mTORC2 in conferring the augmented Nav1.2 channel function caused by hyperactive mTOR signaling induced via pharmacological inhibition of PTEN. To that end, we employed RMC-5552 [52]. Crucially, RMC-5552 was previously established to be selective for mTORC1 at a concentration of 1 nM, whereas at 50 nM, it inhibits both mTORC1 and mTORC2 [52]. At 1 nM, RMC-5552 had no attenuating effect on the augmented Nav1.2 current levels caused by hyperactive mTOR signaling (Figure 1A–C). It also did not attenuate the depolarizing shift in the voltage-dependence of inactivation of Nav1.2-mediated INa caused by hyperactive mTOR signaling (Figure 1F,G). In contrast, at 50 nM, RMC-5552 reversed the augmentation of Nav1.2-mediated INa induced by hyperactivation of mTOR signaling (Figure 1A–C). It also reversed the depolarizing shift in the voltage-dependence of inactivation induced by hyperactive mTOR signaling (Figure 1F,G). To complement our pharmacological approach, we next sought to determine if genetic knockdown of Rictor (mTORC2) would block the effects of hyperactive mTOR signaling on Nav1.2 channel function. To this end, HEK-Nav1.2 cells were transfected with either a previously validated short hairpin containing a GFP reporter that selectively and efficiently knocks down Rictor (shRictor-GFP) [43], or a control short hairpin with a GFP reporter (shCTRL-GFP). 72 h post-transfection, voltage-clamp recordings were performed in GFP positive HEK-Nav1.2 cells that were treated acutely (2 h) with 500 nM VO-Ohpic (PTEN inhibitor) or its vehicle (DMSO). Reproducing the results shown in Figure 1, we found that HEK-Nav1.2 cells transfected with shCTRL-GFP that were treated with a PTEN inhibitor displayed augmented levels of Nav1.2-mediated INa compared to cells treated with the vehicle (Figure 2A–C). Also similar to the results shown in Figure 1, whereas hyperactivated mTOR signaling induced by inhibition of PTEN had no effect on the voltage-dependence of activation of Nav1.2-mediated INa in HEK-Nav1.2 cells transfected with shCTRL-GFP (Figure 2D,E), VO-Ohpic treatment induced a marked depolarizing shift in the voltage-dependence of inactivation of Nav1.2-mediated INa in these cells (Figure 2F,G). In contrast, unlike the effects of PTEN inhibition when tested in HEK-Nav1.2 cells expressing Rictor, hyperactivation of mTOR signaling with VO-Ohpic had no effect on Nav1.2-mediated current levels when tested in HEK-Nav1.2 cells transfected with shRictor-GFP, which showed Nav1.2 current levels resembling those observed in the shCTRL-GFP + DMSO condition (Figure 2A–C). In addition, genetic knockdown of Rictor blocked the depolarizing shift in the voltage-dependence of inactivation of Nav1.2-mediated INa induced by PTEN inhibition, and the V1/2 of inactivation in the shRictor-GFP + PTEN inhibition condition was similar to that observed in the shCTRL-GFP + DMSO condition (Figure 2F,G). These results demonstrate that hyperactive mTOR signaling augments Nav1.2 channel function via mTORC2 signaling. Furthermore, given that the effects of genetic knockdown of Rictor (mTORC2) are identical to the effects of 50 nM RMC-5552 treatment as it relates to blocking the effects of mTOR hyperactivation on Nav1.2 channel function, the results of the genetic knockdown analyses validate that the results achieved via the pharmacological approach are achieved via inhibition of mTORC2. To ensure that the effects of 50 nM RMC-5552 were mediated via modulation of Rictor (mTORC2), we tested 50 nM RMC-5552 in HEK-Nav1.2 cells transfected with shRictor-GFP. Unlike HEK-Nav1.2 cells with intact Rictor expression, in which 50 nM RMC-5552 suppressed elevated current levels induced by PTEN inhibition, 50 nM RMC-5552 had no effect on the peak INa density when Rictor was knocked down, as evidenced by the lack of effect on this parameter when comparing between HEK-Nav1.2 cells expressing shRictor-GFP that were treated with 500 nM VO-Ohpic and 50 nM RMC-5552 versus HEK-Nav1.2 cells expressing shRictor-GFP that were treated with 500 nM VO-Ohpic and the vehicle of RMC-5552 (DMSO; Figure 2A–C). In addition, unlike HEK-Nav1.2 cells with intact Rictor expression, in which 50 nM RMC-5552 reversed the depolarizing shift in the voltage-dependence of inactivation induced by PTEN inhibition, 50 nM RMC-5552 had no effect on the V1/2 of inactivation when Rictor was knocked down, as evidenced by no difference in this parameter when comparing between HEK-Nav1.2 cells expressing shRictor-GFP that were treated with 500 nM VO-Ohpic and 50 nM RMC-5552 versus HEK-Nav1.2 cells expressing shRictor-GFP that were treated with 500 nM VO-Ohpic and the vehicle of RMC-5552 (DMSO; Figure 2F,G). Given that the effects of 50 nM RMC-5552 on Nav1.2-mediated INa require intact Rictor expression, these results highlight mTORC2 as the pharmacological target of the inhibitor at this concentration. To further complement our pharmacological approach, we tested the effects of genetic knockdown of PTEN on Nav1.2-mediated INa. To this end, we transfected HEK-Nav1.2 cells with a short hairpin with a GFP reporter that has been validated to efficiently knock down PTEN and hyperactivate mTOR signaling [44]. Similar to pharmacological inhibition of PTEN with 500 nM VO-Ohpic, genetic knockdown of PTEN resulted in an augmentation of Nav1.2-mediated INa, as evidenced by the increase in peak INa density when comparing between HEK-Nav1.2 cells transfected with shPTEN-GFP versus HEK-Nav1.2 cells transfected with shCTRL-GFP (Figure 3A–C). Also similar to VO-Ohpic, genetic knockdown of PTEN had no effect on the voltage-dependence of activation (Figure 3D,E) and induced a depolarizing shift in the voltage-dependence of inactivation (Figure 3F,G). Given the phenotypic convergence of pharmacological inhibition of PTEN with VO-Ohpic and genetic knockdown of PTEN on Nav1.2-mediated INa, these results highlight PTEN inhibition as the shared molecular mechanism driving the changes in Nav1.2 channel function. To ensure that PTEN is the pharmacological target of 500 nM VO-Ohpic, we tested 500 nM VO-Ohpic in conditions in which PTEN was knocked down. Unlike in HEK-Nav1.2 cells with intact PTEN expression, in which 500 nM VO-Ohpic augments Nav1.2 current levels, VO-Ohpic has no effect on the peak INa density when PTEN is knocked down, as evidenced by a lack of effect when comparing this parameter between cells transfected with shPTEN-GFP treated with 500 nM VO-Ohpic versus cells transfected with shPTEN-GFP treated with the vehicle of VO-Ohpic (DMSO; Figure 3A–C). Similarly, unlike in HEK-Nav1.2 cells with intact PTEN expression, in which 500 nM VO-Ohpic induced a depolarizing shift in the voltage-dependence of inactivation, VO-Ohpic had no effect on the V1/2 of inactivation when PTEN was knocked down, as evidenced by this parameter remaining unchanged when comparing between HEK-Nav1.2 cells transfected with shPTEN-GFP treated with 500 nM VO-Ohpic versus HEK-Nav1.2 cells transfected with shPTEN-GFP treated with the vehicle of VO-Ohpic (DMSO; Figure 3F,G). Given that VO-Ohpic no longer affects the peak INa density and the voltage-dependence of inactivation when PTEN is knocked down, this highlights PTEN as the pharmacological target of 500 nM VO-Ohpic. To ensure that the effects of knocking down PTEN on Nav1.2-mediated INa were driven by hyperactive mTOR signaling, we tested the effects of 50 nM RMC-5552 in HEK-Nav1.2 cells transfected with shPTEN-GFP. Crucially, the augmentation of the peak INa density induced by transfection of HEK-Nav1.2 cells with shPTEN-GFP was reversed by acute (2 h) treatment with 50 nM RMC-5552, with the peak INa density level in the shPTEN-GFP + 50 nM RMC-5552 condition being comparable to the shCTRL-GFP + DMSO condition (Figure 3A–C). Similarly, the depolarizing shift in the voltage-dependence of inactivation induced by transfecting HEK-Nav1.2 cells with shPTEN-GFP was reversed by 50 nM RMC-5552 treatment, with the V1/2 of inactivation values in the shPTEN-GFP + 50 nM RMC-5552 condition being comparable to values observed in the shCTRL-GFP + DMSO condition (Figure 3F,G). Given that the effects of knocking down PTEN are reversible by mTORC2 inhibition, these results highlight hyperactive mTOR signaling induced by genetically inhibiting PTEN as the critical event driving the observed changes in Nav1.2 channel function. mTORC2’s regulatory effects are selective for the Nav1.2 channel among major brain Nav channel isoforms A previous study showed that mTORC2 regulates the phosphorylation of three residues of the Nav1.2 channel [27]. These three residues are Ser544 and Ser561 on the I-II linker, as well as Ser1931 on the C-terminal domain [27], and all three phospho-sites are conserved across murine and human species. Based upon this orthologous overlap, we performed a sequence alignment to determine if these residues were conserved among the other two principal brain Nav channel isoforms; namely, the Nav1.1 channel and the Nav1.6 channel. The homology sequence alignment revealed that Nav1.2S561 is conserved among the brain Nav channel isoforms (corresponding with Nav1.1S558 and Nav1.6S549). However, Nav1.2S544 is not conserved in Nav1.1 (corresponding residue is Nav1.1N541) or Nav1.6 (corresponding residue is Nav1.6N534), and Nav1.2S1931 is also not conserved in Nav1.1 (corresponding residue is Nav1.1F1940) or Nav1.6 (corresponding residue is Nav1.6F1915). The observation that two of the three residues on the Nav1.2 channel that display mTORC2-regulated phosphorylation are not conserved among the three isoforms prompted us to test whether mTORC2’s regulation of the Nav1.2 channel might be selective for Nav1.2 among brain Nav channel isoforms. To this end, we performed patch-clamp recordings in previously validated HEK293 cell lines that stably express either the Nav1.1 channel [41] or the Nav1.6 channel [42]. Similar to the study above, we first treated cells with a pharmacological inhibitor of PTEN (VO-Ohpic; concentration: 500 nM) for 2 h to hyperactivate mTOR signaling. Unlike the findings in HEK-Nav1.2 cells, hyperactivating mTOR signaling via pharmacological PTEN inhibition produced no effect on the current amplitudes of Nav1.1-mediated INa (Figure 4A–C) or Nav1.6-mediated INa (Figure 4H–J). In addition, pharmacological inhibition of PTEN did not affect the voltage-dependence of activation of Nav1.1-mediated INa (Figure 4D,E) or Nav1.6-mediated INa (Figure 4K,L), and also did not affect the voltage-dependence of inactivation of Nav1.1-mediated INa (Figure 4F,G) or Nav1.6-mediated INa (Figure 4M,N). Furthermore, neither 1 nM nor 50 nM RMC-5552 produced any effects on levels of Nav1.1-mediated INa (Figure 4A–C) or Nav1.6-mediated INa (Figure 4H–J). Finally, neither concentration of RMC-5552 affected the voltage-dependence of activation of Nav1.1-mediated INa (Figure 4D,E) or Nav1.6-mediated INa (Figure 4K,L), nor altered the voltage-dependence of inactivation of Nav1.1-mediated INa (Figure 4F,G) or Nav1.6-mediated INa (Figure 4M,N). Collectively, these results demonstrate that among brain Nav channel isoforms, mTORC2’s regulatory effects are selective for the Nav1.2 channel. Neocortical pyramidal neurons in slices from 4–5-month-old J20 mice display augmented Nav1.2 channel function and hyperexcitability through a mechanism requiring mTORC2 activity mTOR signaling is elevated in the early-stage AD brain, as evidenced by increased phosphorylation of downstream mTOR targets, including AktSer473, which represents the major downstream target of mTORC2 [28]. In addition, levels of growth factors that hyperactivate mTOR signaling, such as vascular endothelial growth factor (VEGF), which has been shown to promote hyperexcitability [53], are increased in murine models of early-stage AD neuropathology [54]. Having shown above that hyperactive mTOR signaling selectively increases Nav1.2 channel function in heterologous cells, we next tested whether elevated levels of mTOR signaling would increase the levels of Nav1.2-mediated INa of neocortical pyramidal neurons in brain slices from 4 to 5 month-old J20 mice, a time point when AD neuropathology has been previously shown to be pre-plaque deposition [8] while displaying robust cortical hyperexcitability [7]. For these recordings, we examined layer II/III pyramidal neurons of the anterior cingulate cortex (ACC). We targeted this region because the ACC shows the most age-related brain metabolic dysfunction [55], which leads to oxidative stress and increased levels of growth factors that hyperactivate mTOR signaling, such as VEGF. To measure INa levels of pyramidal neurons, we employed a previously described voltage-clamp protocol designed to obtain well-clamped INa of neurons in the slice preparation while minimizing space-clamp issues [56]. In this protocol, a pre-pulse is employed to activate all Nav channels, followed by a brief return to the holding potential. During this time period, Nav channels proximal to the recording pipette have recovered from inactivation and are available to re-open upon subsequent stimulation, whereas those channels distal from the recording pipette remain inactivated due to the spatiotemporal spread of voltage through the neuron [56,57]. To isolate the Nav1.2-mediated component of the INa, recordings were performed in the presence of selective blockers of the Nav1.1 channel (ICA12142; 1 µM) and Nav1.6 channel (AHTTX; 100 nM), which are the other two principal brain Nav channel isoforms. When comparing the level of Nav1.2-mediated INa current between ACC pyramidal neurons in slices from 4- to 5-month-old J20 mice and age-matched wild-type (WT) control mice, we found that levels of Nav1.2-mediated INa were significantly increased in the J20 mutant neurons (Figure 5A–C). While there was no difference in the voltage-dependence of activation of Nav1.2-mediated INa between the two groups (Figure 5D,E), the voltage-dependence of inactivation of Nav1.2-mediated INa of J20 ACC pyramidal neurons was significantly depolarized compared to the age-matched control cohort (Figure 5F,G). Notably, these electrophysiological phenotypes are identical to the effects observed in the HEK-Nav1.2 cells with hyperactive mTOR signaling. We next dissected the potential contribution of mTORC1 versus mTORC2 to this augmentation of Nav1.2 channel function in J20 ACC pyramidal neurons. Slices were first incubated for 2 h with 1 nM RMC-5552, a concentration previously shown to be selective for mTORC1 [52]. 1 nM RMC-5552 did not attenuate the increased levels of Nav1.2-mediated INa present in the J20 neurons (Figure 5A–C). Similarly, 1 nM RMC-5552 did not reverse the depolarizing shift in the voltage-dependence of inactivation of Nav1.2-mediated INa (Figure 5F,G). Next, slices were incubated for 2 h with 50 nM RMC-5552, a concentration previously shown to inhibit both mTORC1 and mTORC2 signaling [52]. Crucially, 50 nM RMC-5552 reversed the augmented levels of Nav1.2-mediated INa observed in J20 neurons and restored the current levels to a level comparable to the WT condition (Figure 5A–C). In addition, 50 nM RMC-5552 attenuated the depolarizing shift in the voltage-dependence of inactivation of Nav1.2-mediated INa observed in the J20 neurons and restored the V1/2 of inactivation to a level comparable to control neurons (Figure 5F,G). Collectively, these results show that ACC pyramidal neurons in slices from J20 mice display augmented Nav1.2 channel function driven by a mechanism requiring mTORC2 activity. Previous studies have related excess Nav1.2 channel current in cortical pyramidal neurons with increased neuronal excitability and aberrant somatodendritic spike propagation that interferes with neuronal integration and plasticity [58]. Accordingly, we reasoned that the elevated Nav1.2 current observed in ACC pyramidal neurons of 4–5-month-old J20 mice could contribute to altered firing patterns. To test this, we performed whole-cell current clamp recordings and observed that J20 neocortical pyramidal neurons display a robust increase in action potential (AP) firing over a range of injected current stimuli compared to WT neurons (Figure 6A–C). While AP firing as a function of injected current stimuli was increased in the pyramidal neurons from J20 mice, differences in passive electrical properties, including the membrane time constant (tau; Figure 6D) and input resistance (Rin; Figure 6E), which are properties primarily regulated by ion channels other than Nav channels, were not different when comparing between ACC pyramidal neurons in slices from WT mice versus J20 mice. Finally, we dissected the potential contribution of mTORC1 versus mTORC2 to the hyperexcitability observed in J20 neurons. Incubating J20 slices for 2 h with 1 nM RMC-5552 (mTORC1 selective inhibition [52]) had no effect on the hyperexcitability of ACC pyramidal neurons (Figure 6A–C). In contrast, incubating J20 slices for 2 h with 50 nM RMC-5552 (mTORC1 and mTORC2 inhibition [52]) reversed the hyperexcitability and restored the AP discharge to a level comparable to the WT genotype (Figure 6A–C). These results demonstrate that mTORC2 plays a salient role in contributing to the hyperexcitability of ACC pyramidal neurons in early-stage AD neuropathology. Discussion mTORC2-Nav1.2 signaling in AD and mTORopathies Genetic deletion of Rictor in murine seizure models has demonstrated that mTORC2 is critically sufficient to drive mTOR-mediated network hyperexcitability in vivo [26,27]. Here we reproduce a similar finding in vitro and provide a mechanistic explanation involving hyperactive Nav1.2 channel function as a plausible mediator of previously reported in vivo findings [26,27]. In particular, we identify the mTORC2-Nav1.2 interaction as a key step in a cellular signaling mechanism that contributes to intrinsic neuronal membrane hyperexcitability and extend the finding to early-stage AD. By regulating one of the earliest biomarkers of AD progression, inhibition of this step may prove effective in slowing the trajectory of AD neuropathology and associated decline of cognitive function, as well as other neurological disorders featuring hyperactivation of mTOR signaling. Excessive mTOR signaling due to loss-of-function (LoF) mutations in genes encoding negative upstream regulators of mTOR, including PTEN and tuberous sclerosis complex (TSC1/2), frequently lead to cortical hyperexcitability [59,60]; however, the downstream membrane targets of mTOR that mediate the hyperexcitability remained undefined. Here, we find that hyperactive mTOR signaling increases Nav1.2 channel function and that this effect is blocked by pharmacological and genetic inhibition of mTORC2 but not mTORC1, underscoring a central role of mTORC2 signaling in conferring this cellular phenotype. This finding is notable because it highlights increased Nav1.2 channel function as a candidate driver of hyperexcitability across a broad range of diseases characterized by dysfunctional mTOR signaling [61]. mTORC2’s selective regulation of the Nav1.2 channel mTORC2 signaling increases the phosphorylation of Nav1.2S544 and Nav1.2S1931 [27], which are conserved across murine and human species. However, these two phospho-sites are not conserved in Nav1.1 or Nav1.6 sequences, which likely underlies the selectivity of mTORC2 signaling for the Nav1.2 channel among brain Nav channel isoforms. Thus, pharmacologically targeting these residues could be an effective strategy to develop selective modulators of the Nav1.2 channel, similar to the success of pharmacologically targeting interactions between the Nav1.6 channel and its auxiliary proteins in developing Nav1.6 selective modulators [9,48]. Since genetic deletion of Rictor reduces phosphorylation of these Nav1.2 channel residues in vivo [27], and phosphorylation of the Nav1.2 channel has been shown to confer complex functional regulation [62], we posit that excess mTOR signaling increases Nav1.2 channel function by altering channel phosphorylation at these sites, although other mechanisms are possible. For example, manipulating mTOR signaling could alter the complex assembly of mTORC2 with the Nav1.2 channel, and changes in this physical interaction could contribute to the observed functional changes. Likewise, an increase in Nav1.2 channel trafficking and stabilization in the membrane caused by hyperactive mTOR signaling could account for elevated INa but would not easily explain the biophysical changes in the voltage-dependence of inactivation. A combination of these possibilities might also be in play. Thus, future studies are warranted to dissect the residues of the Nav1.2 channel that are phosphorylated by mTORC2 that confer increased channel function and to understand how the protein/protein interaction between mTORC2/Nav1.2 directly affects channel function. While mTOR has not specifically been studied in the context of ion channel trafficking, mTOR has been shown to regulate trafficking of other proteins to the plasma membrane, such as glucose transporters [63]. mTORC2 subcellularly localizes primarily to endosomal vesicles and the plasma membrane, as well as the mitochondria [64], making it conceivable that mTORC2 might regulate the trafficking of the Nav1.2 channel to the plasma membrane. Given that the density of ion channels at the plasma membrane is tightly regulated by endosomal trafficking [65], it is possible that mTORC2’s direct protein/protein interaction with the Nav1.2 channel within the endosome helps facilitate its trafficking to the membrane. Investigations into whether mTORC2 regulates Nav1.2 channel trafficking to the plasma membrane through such a mechanism are warranted in future investigations. While alterations in Nav1.2 channel trafficking by mTORC2 are possible and could contribute to the observed phenotypes, the preponderance of evidence at present points toward mTORC2 affecting Nav1.2 channel via phosphorylation. For example, it has been shown that Rictor (mTORC2) forms a direct protein/protein interaction with the Nav1.2 channel [27]. Furthermore, in the study by Okoh et al. [27], the authors find that phosphorylation of the Nav1.2 channel is reduced in the cortex of mice with forebrain deletion of Pten and Rictor compared to mice with forebrain deletion of Pten and Raptor. In addition, the lack of conservation of two of the residues of the Nav1.2 channel that are differentially phosphorylated by Rictor knockdown among CNS Nav channel isoforms provides a plausible basis for the selectivity of mTORC2’s regulation of the Nav1.2 channel. Given these results, in tandem with the data presented here, it appears most likely that mTORC2’s direct protein/protein interaction with the Nav1.2 channel enables mTORC2 to directly phosphorylate the channel and alter its function. Future studies that employ phospho-null mutations to the residues of the Nav1.2 channel that are differentially phosphorylated on account of Rictor knockdown are warranted to validate the proposed phosphorylation mechanism. Related to the effects of mTOR complexes on membrane excitability, Chen et al. [26] reported that mice with forebrain deletion of Pten display hyperexcitability at the single cell level, and that this phenotype is reversed by concomitant knockdown of Rictor (mTORC2), but not Raptor (mTORC1). While this finding alone does not implicate mTORC2’s downstream regulation of the Nav1.2 channel as the mediator of increased membrane excitability, our findings that pharmacological and genetic inhibition of Rictor (mTORC2) reverse augmented Nav1.2 channel function induced by pharmacological and genetic inhibition of PTEN positions this mechanism as a plausible contributor to the change in membrane excitability, especially considering that mTORC2’s regulatory effects are, among the main CNS Nav channel isoforms, selective. Future research to develop targeted pharmacological manipulations that specifically alter the protein/protein interaction between Rictor (mTORC2) and the Nav1.2 channel will definitively determine how the direct complex formation contributes to altered channel function and membrane excitability. As noted above, Okoh et al. [27] previously showed the Rictor (mTORC2), but not Raptor (mTORC1), forms a direct protein/protein interaction with the Nav1.2 channel. In addition, that study found that concomitant forebrain knockdown of Rictor in mice with forebrain knockdown of Pten resulted in a decrease in Nav1.2 channel phosphorylation, with three residues of the Nav1.2 channel showing differential levels of phosphorylation [27], two of which are not conserved among the other main Nav channel isoforms expressed in the brain. Our data showing that mTORC2’s regulation is selective for the Nav1.2 channel, in tandem with the findings from the Okoh et al. study [27] leads us to posit that mTORC2’s regulation of the Nav1.2 is conferred by mTORC2 directly interacting with the Nav1.2 channel and altering its phosphorylation status. While mTORC2’s regulation of the Nav1.2 channel could occur through an indirect mechanism, this is unlikely. For example, it is possible that mTORC2’s regulation of the Nav1.2 channel could be conferred by modulating the GSK3β/Akt signaling axis, since Akt is the major downstream target of mTORC2 [29]. While possible, the GSK3β/Akt signaling axis has been shown to regulate multiple Nav channel isoforms, including Nav1.2 [40] and Nav1.6 [66,67], whereas the regulation that we observe is selective for the Nav1.2 channel. Thus, while remaining possible that the regulatory effects observed in the present investigation could be due to indirect modulation of pathways such as the GSK3β/Akt axis, our selectivity data argue against this and in favor of mTORC2’s regulatory effects on Nav1.2 channel function being mediated via direct binding and phosphorylation. Complexity of Scn2a genotypic–phenotypic relationships in hyperexcitability disorders Both LoF and gain-of-function (GoF) mutations in the Scn2a gene, which encodes the Nav1.2 channel, have been extensively studied in the context of epilepsy [68], a circuit synchronization disorder that accelerates AD neuropathology [69,70]. Functional analyses of these variants have led to a complex picture in which Scn2a mutations that cause channel GoF [71], LoF [72], or combinations of both [73] can lead to network hyperexcitability. In addition to epilepsy, Scn2a is prominent among genes mostly highly associated with autism spectrum disorder (ASD) [74,75] and a working hypothesis has emerged in which Scn2a GoF mutations tend to be associated with developmental and epileptic encephalopathies [71] while LoF mutations tend to be associated with later onset epilepsy or ASD without epilepsy [76]. Despite this, some variants defy classification [77], and this dichotomy is not universal [78]. While mutational analyses of Scn2a and the Nav1.2 channel have been extensively studied in the context of epilepsy and ASD, their study in the context of secondary targets of mTOR dysregulation remains limited. The role of Nav1.2 channel dysregulation in early-stage AD is of particular interest, given a recent report identifying Scn2a as a top gene differentially enriched in human AD brain [79]. Additionally, the expression level of proteins that increase Nav1.2 channel function and thereby contribute to hyperexcitability, such as calcium/calmodulin protein kinase II (CaMKII) [80] are regulated by mTOR signaling [81] and are dysregulated in subjects with MCI [82], further warranting study of the mTORC2/Nav1.2 interaction in contributing to early-stage AD hyperexcitability. While our finding that mTORC2’s regulation of the Nav1.2 channel is an important contributor to early-stage hyperexcitability in the J20 mouse model of AD neuropathology, J20 mice do not display significant spontaneous tau hyperphosphorylation or neurofibrillary tangles, which could influence the mTORC2-Nav1.2 axis’s regulatory effects on membrane hyperexcitability in the context of AD neuropathology. Synaptic proteins that are altered in AD and linked to Scn2a and mTORC2 In addition to the recent discovery of Scn2a as a top gene differentially enriched in human AD brain [79], other synaptic proteins that are altered in AD and are linked to both Scn2a and mTORC2 have previously been identified. For example, the function of metabotropic glutamate receptors (mGluRs) that control long-term depression (LTD), a form of neuronal plasticity shown to be altered in some murine models of AD neuropathology [83], is regulated by Rictor (mTORC2) but not Raptor (mTORC1), with genetic inhibition of Rictor significantly reducing LTD [84]. Notably, the two main mGluRs that contribute to LTD are mGluR1 and mGluR5, which regulate the trafficking and internalization of the ionotropic glutamate receptors AMPA and NMDA that control excitatory synapse strength [85]. Crucially, the functions of mGluR1, mGluR5, AMPA receptors, and NMDA receptors are all linked to Rictor (mTORC2) [84,86,87] and display aberrant activity in the context of AD [86,88–90]. In addition to being linked to Rictor (mTORC2) and displaying aberrant activity in AD neuropathology, the activity of these synaptic receptors and ion channels are influenced by back propagating action potentials [91,92], a process tightly regulated by the Nav1.2 channel [93]. Thus, the impact of mTORC2’s dysregulation of Nav1.2 channel kinetics could impair synaptic integration by modulating the activity of synaptic metabotropic and ionotropic glutamate receptors. Future studies investigating the effects of the mTORC2-Nav1.2 signaling axis on synaptic integration in the context of early-stage AD and other disorders may provide a more complete picture of circuit dysfunction underlying cognitive impairment. Targeting the mTORC2-Nav1.2 channel interaction as a therapeutic strategy Hyperexcitability is particularly manifest in the 10–22% of AD patients that develop unprovoked seizures [94]. Crucially, genetic and therapeutic inhibition of Rictor (mTORC2) has been shown to regulate multiple electrophysiological processes, including synaptic function [84] and network hypersynchrony [26,27] that become corrupted to produce early circuit instability in AD, which is increasingly being recognized as a driver of cognitive decline in AD [1]. This study adds to this body of literature by showing that, in addition to synaptic function and network hypersynchrony, Rictor (mTORC2) also regulates membrane hyperexcitability at the single cell level via regulation of the function of the Nav1.2 channel, underscoring that Rictor (mTORC2) regulates electrophysiological activity at multiple levels. Given this multi-level regulation of electrophysiological activity by Rictor (mTORC2), it is well positioned as a pharmacological target to reverse hyperexcitability in early-stage AD, and thereby potentially halt or reverse cognitive decline and disease progression. In particular, as it relates to mTORC2’s regulation of intrinsic membrane hyperexcitability at the single-cell level, we found that ACC pyramidal neurons in slices from the J20 AD mouse model display augmented levels of Nav1.2 channel function and neuronal hyperexcitability and that these phenotypes are rapidly reversible by pharmacological inhibition of mTORC1 and mTORC2 but not mTORC1 alone, suggesting a key role of mTORC2 in regulating these electrophysiological effects. The findings are notable in that they provide new mechanistic insight into how modulating mTOR signaling could be efficacious in treating AD and other disorders of hyperactive mTOR signaling. For example, pre-clinical studies of chronic rapamycin treatment, which inhibits mTORC1 and mTORC2 [30,31], in murine models of AD neuropathology have yielded several hypotheses regarding how modulation of mTOR signaling could improve cognitive deficits in early-stage AD, such as by reducing amyloid oligomers and tauopathy [95,96], restoring cerebral blood flow and brain vascular density [97], normalizing synaptic plasticity [98] and restoring blood–brain barrier function [32]. While these actions are assuredly pertinent, hyperexcitability emerges in mouse models before many of these hallmarks of AD neuropathology, including the deposition of amyloid beta plaques and changes in synaptic function [16]. In addition to temporal precedence, hyperexcitability is known to actively promote many of these changes, including increasing the production and release of amyloid beta [99], tau deposition [100] and contributing to blood–brain barrier disruption [101]. Thus, the mTORC2-Nav1.2 signaling pathway is a sufficient but likely non-exclusive contributor to progressive neural circuit pathology, and is crucial to consider in the context of understanding how mTOR signaling modulators, such as rapamycin, which is currently being evaluated in clinical trials of early-stage AD [34], may be efficacious in improving cognitive function.